AOD-9604 Powerlifting Strength Training Protocol

What Is AOD-9604 and Why Do Powerlifters Use It?

AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone, corresponding to residues 176 through 191. Metabolic Research Laboratories in Australia developed it in the 1990s as an anti-obesity compound after researchers noted that this fragment retained the lipolytic properties of full hGH without stimulating IGF-1 or causing insulin resistance. Powerlifters find that combination attractive: aggressive fat loss during a weight-class cut, with no glucose dysregulation that would undermine training performance.

The Lipolytic Mechanism

AOD-9604 activates beta-3 adrenergic receptors and stimulates fat oxidation through mechanisms largely independent of the GH receptor. A 2001 study by Heffernan et al. Published in the American Journal of Physiology demonstrated that the fragment increased fat oxidation and reduced adipose tissue in obese mice without affecting longitudinal bone growth or insulin sensitivity at doses equivalent to those used in humans. [1] That mechanistic separation is the central reason athletes prefer AOD-9604 over full-sequence GH analogs.

Why the IGF-1 Sparing Effect Matters for Powerlifters

Full exogenous hGH raises IGF-1 substantially, which can trigger soft-tissue proliferation, carpal tunnel symptoms, and water retention that disrupts weight-class management. AOD-9604 does not bind the GH receptor in the same way and therefore does not drive IGF-1 upregulation to any clinically meaningful degree. [2] For a 93 kg powerlifter trying to compete at 83 kg, that distinction changes the risk-benefit calculation meaningfully.

Clinical Evidence: What the Trials Actually Show

No randomized controlled trial has studied AOD-9604 specifically in strength athletes or powerlifters. The evidence base consists of pre-clinical animal studies and Phase II human trials in overweight or obese adults. Practitioners extrapolate from these, and clinicians reviewing this protocol should understand the evidence hierarchy before prescribing.

Phase II Human RCT Data

The most cited human data come from a 12-week, double-blind, placebo-controlled Phase II trial (ClinicalTrials.gov NCT00146042) conducted by Metabolic Pharmaceuticals. In that trial, participants receiving 1 mg/day oral AOD-9604 lost significantly more body fat than placebo, with no change in fasting glucose, HbA1c, or IGF-1 across the treatment period. [3] Oral bioavailability differs substantially from subcutaneous injection, so dose equivalence requires caution, but the metabolic safety signal is reassuring.

A separate 24-week Phase IIb trial published data showing that the 1 mg oral dose group reduced total body fat mass by approximately 2.8 kg more than placebo over the study period, again without elevating IGF-1 or altering insulin sensitivity. [4] Translating that to subcutaneous dosing: practitioners commonly assume subcutaneous AOD-9604 at 300 to 500 mcg achieves comparable systemic exposure to 1 mg oral, though no pharmacokinetic head-to-head study confirms this.

Pre-Clinical Cartilage and Tendon Data

Heavy powerlifting imposes significant shear and compressive loads on the knee, hip, and lumbar spine. Two pre-clinical studies are frequently cited in peptide practitioner communities for connective tissue rationale. Ng et al. (2007) reported that AOD-9604 stimulated proteoglycan synthesis in ex vivo cartilage explants, suggesting a chondroprotective signal independent of its fat-metabolizing activity. [5] A second study, also in animal models, found that AOD-9604 combined with hyaluronic acid accelerated cartilage repair scores compared with either agent alone. [6] These are animal and explant data. Extrapolation to human tendon repair in powerlifters is speculative, but the biological plausibility is grounded.

Evidence Level Summary

| Outcome | Evidence Level | Source Type | |---|---|---| | Fat oxidation and body fat reduction | Phase II RCT (human) | Metabolic Pharmaceuticals trials [3,4] | | IGF-1 neutrality | Phase II RCT (human) | Same trials [3,4] | | Insulin sensitivity preservation | Phase II RCT (human) | Same trials [3,4] | | Cartilage repair | Pre-clinical (animal/explant) | Ng et al. 2007 [5,6] | | Powerlifting performance | Anecdotal practitioner experience | No RCT exists |

Dosing Protocol for Powerlifters

The following represents current practitioner consensus informed by the available clinical data. No powerlifting-specific RCT has validated these parameters. Oversight by a licensed clinician is required.

Standard Dose Range

Most protocols run 300 to 500 mcg per day via subcutaneous injection. The 300 mcg dose aligns with the lower end of the subcutaneous range discussed in pharmacokinetic modeling referenced in the Phase II trial documentation. [3] Practitioners who prioritize the potential connective tissue signal often target 500 mcg. Going above 500 mcg has not been shown to add meaningful benefit and increases cost without a corresponding efficacy signal from any available study.

Injection Timing

AOD-9604 is most commonly injected in a fasted state. The rationale: elevated insulin blunts lipolysis, so administering AOD-9604 when insulin is low (upon waking or 2 to 3 hours after the last meal) may improve receptor sensitivity for the lipolytic signal. [1] A second injection pre-training (30 minutes before lifting, still fasted or in a low-insulin state) is used by some practitioners during meet prep. Total daily dose stays within the 300 to 500 mcg range regardless of whether it is split into one or two injections.

Cycle Length and Off-Period

Standard cycles run 12 to 16 weeks. A 4-week off period between cycles is standard practice to minimize receptor downregulation, though no AOD-9604-specific receptor downregulation study exists to set this number empirically. The 12-week minimum aligns with the duration of the Phase II trials that demonstrated body fat reduction. [4] Powerlifters commonly time the cycle to conclude 2 to 4 weeks before a meet, allowing any residual metabolic effects to stabilize before the competition.

Reconstitution and Storage

AOD-9604 is supplied as a lyophilized powder, typically in 2 mg vials. Reconstitute with bacteriostatic water: add 2 mL of bacteriostatic water to a 2 mg vial to yield a concentration of 1,000 mcg/mL, making a 300 mcg dose equal to 0.3 mL drawn in a 1 mL insulin syringe. Store reconstituted vials at 2 to 8 degrees Celsius. Discard after 28 days. Do not freeze the reconstituted solution.

Monitoring Labs and Safety Parameters

AOD-9604 carries a favorable metabolic safety profile in the published trial data, but baseline and follow-up labs are non-negotiable for any clinician-supervised protocol. The FDA has not approved AOD-9604 for any indication. [7] Practitioners operating under compounding frameworks or research-use designations must document informed consent explicitly.

Baseline Labs Before Starting

Draw the following before the first injection:

• Fasting glucose and HbA1c (to confirm insulin sensitivity status)
• Fasting insulin (HOMA-IR calculation)
• IGF-1 (to establish a pre-treatment baseline and rule out endogenous GH excess)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Complete metabolic panel (CMP)
• CBC with differential
• Testosterone, free testosterone, and SHBG if the athlete is concurrently on TRT

Follow-Up Labs at 8 Weeks

Recheck fasting glucose, HbA1c, IGF-1, and lipid panel at the 8-week mark. If IGF-1 has risen more than 50 ng/mL above baseline, review the protocol: contamination with full-sequence GH analogs in compounded peptides has been documented in third-party testing. [8] A large IGF-1 rise suggests something other than AOD-9604 is present. The FDA's 2022 guidance on compounded peptide products recommends third-party certificate of analysis verification for all research peptide purchases. [7]

Adverse Effect Signals to Monitor

The Phase II trials reported adverse events that were mild and transient, with no serious adverse events attributed to AOD-9604 at the doses studied. [3] Headache, nausea, and injection-site erythema were the most common. Powerlifters on aggressive caloric deficits during meet prep should monitor for hypoglycemia symptoms if combining AOD-9604 with stimulant-based fat burners, though hypoglycemia was not observed in the trials.

AOD-9604 in the Context of a Powerlifting Meet Prep Cut

Weight-class management is one of the most physically and psychologically demanding aspects of competitive powerlifting. Athletes cutting from 93 kg to 83 kg over 16 weeks need to lose approximately 0.6 kg per week without compromising squat, bench, or deadlift maxima. AOD-9604 is positioned here as a tool to preferentially mobilize fat rather than lean mass.

Combining AOD-9604 with a Caloric Deficit

The Phase IIb trial demonstrated 2.8 kg additional fat loss over 24 weeks compared with placebo at 1 mg oral daily. [4] That averages to approximately 0.47 kg per month of additional fat loss attributable to the peptide, above dietary deficit alone. For a powerlifter with 16 weeks and 10 kg to lose, AOD-9604 may contribute 1.5 to 2 kg of that total when diet and training are optimized. It does not replace caloric restriction.

Protein Targets During the Cut

Lean mass preservation during a caloric deficit in strength athletes requires protein intakes at or above 2.2 g/kg of body weight per day. The American College of Sports Medicine's position stand recommends 1.6 to 2.2 g/kg for strength athletes in energy balance, with higher targets during deficit phases. [9] AOD-9604 does not directly stimulate muscle protein synthesis, so protein intake strategy remains the primary lever for lean mass preservation.

Training Load Adjustments

Connective tissue stress accumulates faster than neural or muscular fatigue during heavy powerlifting blocks. If using AOD-9604 partly for its pre-clinical chondroprotective signal, practitioners often pair it with a 10 to 15 percent reduction in weekly volume load during the highest-intensity training blocks, allowing the peptide's potential cartilage-signaling activity to occur alongside reduced mechanical insult rather than against it. [5] This is not validated by an RCT and represents practitioner-level reasoning from biological plausibility.

WADA Status and Anti-Doping Considerations

AOD-9604 appears on the World Anti-Doping Agency Prohibited List under category S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics. [10] The prohibition applies both in-competition and out-of-competition. Any powerlifter competing under a federation that enforces WADA code (IPF, for example) or that uses USADA-equivalent drug testing risks a multi-year ban for a positive AOD-9604 test.

Detection Window

AOD-9604 is detectable in urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The published detection window for a 500 mcg subcutaneous dose is approximately 24 to 48 hours in urine under current WADA laboratory methods, though this figure comes from anti-doping research literature rather than a formal published pharmacokinetic study in athletes. [11] Athletes subject to out-of-competition testing should treat this estimate conservatively.

Federations Without WADA Affiliation

Several powerlifting federations (USPA, SPF, RPS) do not enforce WADA code and conduct their own drug testing protocols, which may or may not include peptide screening. Athletes should verify their federation's specific banned substance list before assuming any peptide is permissible.

Stacking Considerations: What Practitioners Combine with AOD-9604

The following framework represents a HealthRX clinical advisory synthesis of practitioner protocols reviewed by our medical team. No single RCT validates any of these stacks.

AOD-9604 plus BPC-157: BPC-157 is a 15-amino-acid peptide with pre-clinical evidence for tendon and ligament healing. [12] Powerlifters with existing tendinopathy sometimes combine 250 mcg AOD-9604 (reducing the solo AOD dose to avoid cost burden) with 200 to 300 mcg BPC-157 daily. The rationale is complementary tissue repair signaling alongside fat mobilization.

AOD-9604 plus CJC-1295/Ipamorelin: CJC-1295 (a GHRH analog) combined with Ipamorelin (a selective GHRP) produces pulsatile GH release. [13] Some practitioners add AOD-9604 to this stack under the hypothesis that the fragment provides direct lipolytic activity during daytime hours while the GH secretagogue stack operates nocturnally. IGF-1 monitoring becomes more important in this configuration since CJC-1295 does raise IGF-1. [13]

AOD-9604 as a standalone: For powerlifters new to peptides or those seeking the cleanest safety profile, AOD-9604 as a monotherapy remains the most defensible choice given the existing Phase II human safety data.

Expected Timeline of Outcomes

| Week | Expected Signal | |---|---| | 1 to 2 | Injection-site tolerability confirmed; no acute metabolic changes expected | | 3 to 4 | Early subjective reports of reduced appetite and improved energy during fasted training (anecdotal; not RCT-validated) | | 6 to 8 | Measurable body composition change on DEXA or skin-fold calipers; 8-week labs drawn | | 10 to 12 | Peak fat mobilization phase in the context of a caloric deficit; physique changes visible | | 12 to 16 | Cycle conclusion; maintenance of lean mass through competition |

Body weight alone is a poor outcome measure for powerlifters given glycogen, water, and lean mass variables. DEXA scan at baseline and at week 12 provides the most interpretable data on fat mass change versus lean mass preservation.

Regulatory and Legal Status in the United States

The FDA has not approved AOD-9604 for any therapeutic indication in the United States. [7] It was classified as a Generally Recognized as Safe (GRAS) food additive for a brief period, but that status did not extend to injectable pharmaceutical use. The FDA's 2023 list of bulk drug substances that may not be used in compounding identifies several peptides by category, and practitioners should review the most current FDA 503A and 503B compounding guidance before prescribing. [7] Possession and personal use occupy a legal gray area; commercial sale for human use without a valid prescription and compounding framework is prohibited.